Mediterranean Journal of Hematology and Infectious Diseases

IS IT SAFE AND COST SAVING TO DEFER THE CD4+ CELL COUNT MONITORING IN STABLE PATIENTS ON ART WITH MORE THAN 350 OR 500 CELLS/µL?

Benedetto Maurizio Celesia, Dr., Andrea Marino, Dr., Rosa Fontana del Vecchio, Dr., Roberto Bruno, Dr., Filippo Palermo, Professor, Maria Gussio, Dr., Giuseppe Nunnari, Professor, Bruno Cacopardo, Professor

Abstract 946 | PDF Downloads 582 HTML Downloads 135

Page e2019063

PDF HTML

DOI: https://doi.org/10.4084/mjhid.2019.063

THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.

Sanaa Kamal, Sara Abdelhakam, Dr., Dahlia Ghoraba, Mohamad Amer Mohsen, Ahmed Abdelsalam, Huda Hassan, Leila Nabeigh

Abstract 1071 | PDF Downloads 841 HTML Downloads 135

Page e2019060

PDF HTML

DOI: https://doi.org/10.4084/mjhid.2019.060

The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

Michele Bibas

Abstract 1017 | PDF Downloads 1278 HTML Downloads 275

Page e2024015

PDF HTML

DOI: https://doi.org/10.4084/MJHID.2024.015

Search

Search Results

IS IT SAFE AND COST SAVING TO DEFER THE CD4+ CELL COUNT MONITORING IN STABLE PATIENTS ON ART WITH MORE THAN 350 OR 500 CELLS/µL?

THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.

The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY